Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection

SEATTLE: SEATTLE, Dec. 23, 2021 /PRNewswire/ — Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today published research describing LMN-201, an investigational orally delivered biologic cocktail to prevent C. difficile infection (CDI). LMN-201 combines four therapeutic proteins—manufactured and delivered in the edible microorganism spirulina—that work synergistically to neutralize both the C. difficile bacterium and the toxin that causes its virulence.
Click here to view original post.

Be the first to comment

Leave a Reply

Your email address will not be published.